Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noor Wortelboer

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cancer|December 10, 2025
Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced breast cancerMaryse J Luijendijk, Philippe R Lee Meeuw Kjoe, Noor Wortelboer, et al.
Nature Medicine|September 4, 2025
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trialElisabeth M Jongbloed, Noor Wortelboer, Vanja de Weerd, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trialNoor Wortelboer, Seamus Kent, Inge R Konings, et al.
Nature|November 28, 2024
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancerGabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, et al.
JAMA Oncology|February 19, 2026
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical TrialNoor Wortelboer, Annemiek van Ommen-Nijhof, Inge R Konings, et al.
Nature|July 22, 2025
Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancerGabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, et al.
Journal of the National Cancer Institute|November 21, 2025
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trialNoor Wortelboer, Seamus Kent, Hedwig M Blommestein, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cancer|December 10, 2025
Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced breast cancerMaryse J Luijendijk, Philippe R Lee Meeuw Kjoe, Noor Wortelboer, et al.
Nature Medicine|September 4, 2025
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trialElisabeth M Jongbloed, Noor Wortelboer, Vanja de Weerd, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trialNoor Wortelboer, Seamus Kent, Inge R Konings, et al.
Nature|November 28, 2024
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancerGabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, et al.
JAMA Oncology|February 19, 2026
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical TrialNoor Wortelboer, Annemiek van Ommen-Nijhof, Inge R Konings, et al.
Nature|July 22, 2025
Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancerGabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, et al.
Journal of the National Cancer Institute|November 21, 2025
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trialNoor Wortelboer, Seamus Kent, Hedwig M Blommestein, et al.
Pageof 1